Follows people with blood cancers treated with tisagenlecleucel in Brazil
Observes Brazilian patients with lymphoma or leukemia receiving tisagenlecleucel, a cell therapy.
Plain-language title generated from the registry record
Registry title: Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Key facts
- Where
- Curitiba, Minas Gerais, Salvador, and São Paulo, BrazilSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with relapsed or refractory B-cell cancers (ALL, diffuse large B-cell lymphoma) who received tisagenlecleucel. It follows them over time and does not give a new treatment.
- Age
- 0 to 100 years. For B-cell ALL: 0-17 years (pediatric) or 18-25 years (adults). For diffuse large B-cell lymphoma: 18 years or older.
- Sex
- People of any gender can join.
- Disease stage
- Relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), or relapsed or refractory diffuse large B-cell lymphoma.
- Earlier treatment
- People must have received a tisagenlecleucel infusion, either in the commercial setting or as out-of-specification (OOS) use.
Main reasons for not taking part
- Did not agree to data collection
- Received tisagenlecleucel as part of an interventional clinical trial
Read by machine on 11 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 100 years old?
Source: NCT05541341, who can take part
Where in Brazil
- Curitiba, ParanáHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Minas Gerais, Belo HorizonteHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Salvador, Estado de BahiaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- São PauloHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT05541341
- Record updated
- 10 November 2026
- Original description
This will be a multicenter, national, non-interventional, prospective cohort studyRead full original descriptionShow less
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies: a 15-year Prospective Registry Study on Three Cohorts.
This will be a multicenter, national, non-interventional, prospective cohort study
Inclusion: Patients eligible for inclusion in this study must meet the following criteria:; Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND; Signed informed consent must be obtained prior to participation in study, AND; For ALL participants:; Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR; Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR; For DBLCL and FL participants:; Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.
Exclusion: Patients who received tisagenlecleucel infusion as part of any interventional clinical trial; Patients who did not consent to data collection.